Comparative, Prospective Study Regarding Efficacy, Safety & Adverse Effects of Anti-Asthmatic Drugs in Case of Mild to Moderate Chronic Stable Persistent Bronchial Asthma in Adults.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. www.ginasthma.org

National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138.               

Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19(1):182-91.

Eseverri JL, Botey J, Marin AM. Budesonide: treatment of bronchial asthma during childhood. Allergy Immunol 1995;27(4):129-35.       

Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag 2008;4(6):1201-8.          

Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001;61(9):1325-50.        

Wolfe J, Laforce C, Friedman B, et al. Formeterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand and placebo.  Chest 2006;129(1):27-38.         

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000;356(9237):1255-9.

Tripathi KD. Adverse drug effects. In: Tripathi KD, edr. Essentials of Medical Pharmacology. 6th edn. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2006: p. 78-86.

Chabner BA, Bertino J, Cleary J, et al. Cytotoxic agents. In: Brunton LL, Chabner BA, Knollmann BC, eds. The pharmacological basis of therapeutics. 12th edn. New York: McGraw-Hill Medical Publisher 2011: p. 1677-730.

Uppasala Monitoring Centre. The use of the WHO–UMC system for standardised case causality assessment [monograph on the internet]. Uppsala: Uppsala Monitoring Centre, 2005 [cited 2008 Jul 7]. http://www.WHO‐UMC.org/graphics/4409.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.        

Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalamic pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol 1998;101(3):312-9.             

Nelson HS, Bernstein IL, Fink J, et al. Oral glucocorticosteroid- sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group. Chest 1998;113(5):1264-71.            

Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101(4 Pt 1):457-63.         

Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84(4):417-24.             

Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(39 Suppl):1-34.

Bernstein DI, Hébert J, Cheema A, et al. Efficacy and onset of action of mometasone furoate/ formoterol and fluticasone propionate/ salmeterol combination treatment in subjects with persistent asthma. Allergy Asthma & Clin Immunol 2011;7(1):21.  

Chowdhury BA, Pan DG. The FDA and safe use of long-acting betaagonists in the treatment of asthma. N Engl J Med 2010;362(13):1169-71.  

Walters EH, Gibson PG, Lasserson TJ, et al. Long-acting beta2- agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007;24(1):CD001385.   

O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164(8 Pt 1):1392-7.              

Cote C, Pearle JL, Sharafkhaneh A, et al. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther 2009;22(1):44-9.             

Van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9(8):1684-8.               

Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy 2009;2:63-72.   

Sivasankari V, Manivannan E, Sivakumar V. Comparative study to assess the efficacy and safety of mometasone/ formoterol and budesonide/ formoterol as combination therapy in moderate bronchial asthma patients – a prospective, open label comparative study. Int J Pharm Bio Sci 2016;7(3):1-5.     

Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000;16(5):808-16.                 

Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009;18(1):41-9.             

Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113(1):59-65.             

Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009;124(4):719-23.e1.             

Zeidler M, Corren J, Tashkin DP. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Curr Med Res Opin 2010;26(6):1295-305.